share_log

Virpax Pharmaceuticals | ARS: Annual Report to Security Holders

Virpax Pharmaceuticals | ARS: Annual Report to Security Holders

Virpax制药 | ARS:年度报告
美股SEC公告 ·  06/12 17:13

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals has made an announcement regarding the launch of Epoladerm™, a new non-opioid pain management product. Epoladerm™ is presented as a diclofenac epolamine spray film, specifically formulated to treat acute pain associated with minor injuries such as strains, sprains, and contusions. The company has underscored the significance of Epoladerm™, particularly its non-opioid characteristic and user-friendly spray film application, which aligns with Virpax's dedication to providing alternative pain management options in the midst of the ongoing opioid crisis.
Virpax Pharmaceuticals has made an announcement regarding the launch of Epoladerm™, a new non-opioid pain management product. Epoladerm™ is presented as a diclofenac epolamine spray film, specifically formulated to treat acute pain associated with minor injuries such as strains, sprains, and contusions. The company has underscored the significance of Epoladerm™, particularly its non-opioid characteristic and user-friendly spray film application, which aligns with Virpax's dedication to providing alternative pain management options in the midst of the ongoing opioid crisis.
Virpax药品公司宣布推出Epoladerm™,这是一种新型非阿片类止痛产品。Epoladerm™形式为双氯芬酸左旋门冬氨酸盐喷雾膜,特别配制以治疗与轻微伤患有关的急性疼痛,如扭伤、扭伤和挫伤。公司强调了Epoladerm™的重要性,特别是其非阿片类特征以及用户友好的喷雾膜应用,这符合Virpax在当前阿片类危机中提供替代止痛选择的承诺。
Virpax药品公司宣布推出Epoladerm™,这是一种新型非阿片类止痛产品。Epoladerm™形式为双氯芬酸左旋门冬氨酸盐喷雾膜,特别配制以治疗与轻微伤患有关的急性疼痛,如扭伤、扭伤和挫伤。公司强调了Epoladerm™的重要性,特别是其非阿片类特征以及用户友好的喷雾膜应用,这符合Virpax在当前阿片类危机中提供替代止痛选择的承诺。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息